Ovarian Cancer Screening Trial Still Sees No Death Reduction

Long-term follow-up of a huge randomized trial found that ovarian cancer screening with transvaginal ultrasound alone or in combination with CA125 blood testing did not reduce mortality from the disease compared with no screening, though use of CA125 detected cancers at an earlier stage.

At a median follow-up of 16.3 years, incidence of ovarian or tubal cancer was the same in each of the three groups (1.0%), as was the incidence of ovarian and tubal cancer deaths (0.6%), according to researchers led by Usha Menon, MD, of University College London.

Read more from MedPage Today, by Mike Bassett, about Ovarian Cancer Screening Trial Still Sees No Death Reduction

Chinnapong/Shutterstock.com